Tower Research Capital (TRC)’s AnaptysBio ANAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $65.5K | Sell |
970
-1,928
| -67% | -$117K | ﹤0.01% | 2537 |
|
|
2026
Q1 | $161K | Buy |
2,898
+2,171
| +299% | +$117K | ﹤0.01% | 1793 |
|
|
2025
Q4 | $35.2K | Sell |
727
-1,213
| -63% | -$47.3K | ﹤0.01% | 2692 |
|
|
2025
Q3 | $59.4K | Sell |
1,940
-224
| -10% | -$5.14K | ﹤0.01% | 2391 |
|
|
2025
Q2 | $48K | Buy |
2,164
+1,377
| +175% | +$28.8K | ﹤0.01% | 3012 |
|
|
2025
Q1 | $14.6K | Sell |
787
-1,910
| -71% | -$31.9K | ﹤0.01% | 3277 |
|
|
2024
Q4 | $35.7K | Buy |
2,697
+1,531
| +131% | +$37.1K | ﹤0.01% | 2784 |
|
|
2024
Q3 | $39.1K | Sell |
1,166
-12,168
| -91% | -$416K | ﹤0.01% | 2862 |
|
|
2024
Q2 | $334K | Buy |
13,334
+12,087
| +969% | +$281K | 0.01% | 1660 |
|
|
2024
Q1 | $28.1K | Sell |
1,247
-19,275
| -94% | -$456K | ﹤0.01% | 2707 |
|
|
2023
Q4 | $440K | Buy |
20,522
+16,926
| +471% | +$292K | 0.01% | 1469 |
|
|
2023
Q3 | $64.6K | Buy |
3,596
+2,565
| +249% | +$48.9K | ﹤0.01% | 2335 |
|
|
2023
Q2 | $21K | Buy |
1,031
+169
| +20% | +$3.43K | ﹤0.01% | 3341 |
|
|
2023
Q1 | $19K | Buy |
862
+433
| +101% | +$10.5K | ﹤0.01% | 3469 |
|
|
2022
Q4 | $13K | Sell |
429
-2,702
| -86% | -$76.3K | ﹤0.01% | 3571 |
|
|
2022
Q3 | $80K | Sell |
3,131
-10,707
| -77% | -$251K | ﹤0.01% | 2753 |
|
|
2022
Q2 | $281K | Buy |
13,838
+13,219
| +2,136% | +$293K | 0.01% | 1528 |
|
|
2022
Q1 | $15K | Sell |
619
-1,534
| -71% | -$46.4K | ﹤0.01% | 3793 |
|
|
2021
Q4 | $74K | Buy |
2,153
+1,621
| +305% | +$51.4K | ﹤0.01% | 2446 |
|
|
2021
Q3 | $14K | Sell |
532
-868
| -62% | -$22K | ﹤0.01% | 4019 |
|
|
2021
Q2 | $37K | Sell |
1,400
-3,566
| -72% | -$85.5K | ﹤0.01% | 3274 |
|
|
2021
Q1 | $107K | Buy |
4,966
+3,875
| +355% | +$97.8K | ﹤0.01% | 2537 |
|
|
2020
Q4 | $23K | Sell |
1,091
-3,577
| -77% | -$86.9K | ﹤0.01% | 3768 |
|
|
2020
Q3 | $69K | Buy |
4,668
+1,934
| +71% | +$34.9K | ﹤0.01% | 3392 |
|
|
2020
Q2 | $61K | Buy |
+2,734
| New | +$50K | ﹤0.01% | 2888 |
|
|
2020
Q1 | – | Sell |
-2,419
| Closed | -$39K | – | 3000 |
|
|
2019
Q4 | $39K | Buy |
2,419
+535
| +28% | +$12.7K | ﹤0.01% | 1482 |
|
|
2019
Q3 | $66K | Buy |
+1,884
| New | +$89.6K | ﹤0.01% | 1593 |
|
|
2018
Q3 | – | Sell |
-440
| Closed | -$31K | – | 3727 |
|
|
2018
Q2 | $31K | Sell |
440
-1,755
| -80% | -$147K | ﹤0.01% | 2141 |
|
|
2018
Q1 | $228K | Buy |
+2,195
| New | +$247K | 0.02% | 818 |
|
|
2017
Q4 | – | Sell |
-776
| Closed | -$27K | – | 3476 |
|
|
2017
Q3 | $27K | Buy |
+776
| New | +$20.9K | ﹤0.01% | 2515 |
|
|
2017
Q2 | – | Sell |
-50
| Closed | -$1K | – | 2656 |
|
|
2017
Q1 | $1K | Buy |
+50
| New | +$1.17K | ﹤0.01% | 2755 |
|
Other funds holding ANAB
EC
TCM
AAA
S
WP
6CM
Tower Research Capital (TRC)'s ANAB Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its AnaptysBio (ANAB) stake by 67% in Q2 2026, selling an estimated $117K and leaving 970 shares worth $65.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2537.
Tower Research Capital (TRC) first reported a position in ANAB in Q1 2017 and has held it in 31 quarters since. The position peaked at $440K in Q4 2023. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.
- Tower Research Capital (TRC) held 970 shares of AnaptysBio worth $65.5K as of Q2 2026.
- Tower Research Capital (TRC) sold 1,928 AnaptysBio shares in Q2 2026, an estimated $117K.
- AnaptysBio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2537 holding.
- Tower Research Capital (TRC) first reported a position in AnaptysBio in Q1 2017 and has held it in 31 quarters since.
- Tower Research Capital (TRC)'s AnaptysBio position peaked at $440K in Q4 2023.
- 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.